7 start-ups of the DACH region continue their Catapult journey!

Seven start-ups have been selected for the EIT Health Catapult Semi-finals, ready to make their mark on the European healthcare scene.

We are excited to announce the seven D.A.CH start-ups selected to join the EIT Health Catapult Semi-finals, chosen among the 42 start-ups from across Europe, moving to the next stage of the programme. The D.A.CH Regional Selection concluded with the selection of Ablevia biotech GmbH, PRAMOMOLECULAR GmbH (BioTech), Freiburger Medizintechnik GmbH, Biome Diagnostics GmbH  (MedTech), XUND Solutions GmbH, deepeye Medical GmbH and® by SOFY GmbH (Digital Health) for the semi-finals. The seven selected projects merge technology and product development in ways that are truly innovative, with the potential to create a better future for European citizens.

These are the selected D.A.CH semi-finalists: 

Ablevia biotech GmbH´s team envisions a future where the targeted removal of unwanted and disease-causing antibodies no longer imposes inefficient and stressful restrictions. Their mission is to develop therapeutics for the removal of unwanted and disease-causing antibodies.


PRAMOMOLECULAR GmbH develops self-delivering siRNAs as drug candidates for the treatment of serious cancer and infectious diseases in lung and pancreas, based on its patent-pending platform technology.



Freiburger Medizintechnik GmbH´s  mission is to provide the medical community with innovative technology for highly effective and simple infection control. Their technology is based on the Transient Spark Disinfection, a special form of cold plasma jet designed for application in dentistry.


Biome Diagnostics GmbH  combines state-of-the-art microbiome diagnostics with AI to advance the field of personalized diagnostics and therapeutic approaches. In this way, the company aims to bring sound gut microbiome diagnostics into routine use.

XUND Solutions GmbHXUND Solutions GmbH´s team believes that people, medicine and technology go hand in hand. Their medical device allows to build a digital health assistant that helps customers, patients and employees to understand their symptoms, receive reliable assessments on what could be causing them and take the right next steps.


deepeye Medical GmbH empowers ophthalmologists with AI to provide individual therapy to patients suffering from retinal eye diseases like Age-related Macular Degeneration (AMD) and others with a prevalence of >12% in the European and US population, thus preventing the causes of more than 90% of blindness.® by SOFY GmbH ‘s vision is to create a place where people of all ages and backgrounds who suffer from depression feel well taken care of – so they can beat the disease!

The selected start-ups will receive intensive coaching on their value proposition and investor pitch, and then pitch and compete against the European-wide competition during the EIT Health Catapult semi-finals.